These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

858 related items for PubMed ID: 25908605

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T.
    Ann Oncol; 2017 Nov 01; 28(11):2698-2706. PubMed ID: 29045553
    [Abstract] [Full Text] [Related]

  • 3. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec 01; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y, Kiura K, Hotta K, Takigawa N, Tabata M, Matsuo K, Yoshioka H, Hayashi H, Kawai H, Aoe K, Maeda T, Ueoka H, Tanimoto M.
    J Thorac Oncol; 2010 Sep 01; 5(9):1430-4. PubMed ID: 20651615
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Cho EK, Shin DB, Hoon Lee J.
    Cancer; 2007 Feb 15; 109(4):732-40. PubMed ID: 17211861
    [Abstract] [Full Text] [Related]

  • 7. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S.
    Lung Cancer; 2015 Aug 15; 89(2):146-53. PubMed ID: 26093793
    [Abstract] [Full Text] [Related]

  • 8. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP, Fossella F.
    Cancer; 2005 Dec 15; 104(12):2766-74. PubMed ID: 16288485
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
    Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R.
    Ann Oncol; 2009 Jul 15; 20(7):1249-56. PubMed ID: 19276396
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A, Tokyo Cooperative Oncology Group.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):749-754. PubMed ID: 31070750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
    Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D.
    J Thorac Oncol; 2011 Aug 01; 6(8):1400-6. PubMed ID: 21673602
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M.
    J Thorac Oncol; 2011 Nov 01; 6(11):1907-14. PubMed ID: 22005471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.